Acute onset of fingolimod-associated macular edema

PURPOSE: Fingolimod is among the first oral disease-modifying agents for the treatment of relapsing-remitting multiple sclerosis (MS). Despite its favorable safety profile, fingolimod may cause macular edema, a significant adverse event, which occurs within the first 4 months of therapy. Macular ede...

Descripción completa

Detalles Bibliográficos
Autores principales: Soliman, Mohamed Kamel, Sarwar, Salman, Sadiq, Mohammad A., Jack, Loren, Jouvenat, Neil, Zabad, Rana K., Kedar, Sachin, Nguyen, Quan Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Case report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757484/
https://www.ncbi.nlm.nih.gov/pubmed/29503930
http://dx.doi.org/10.1016/j.ajoc.2016.09.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757484/
https://www.ncbi.nlm.nih.gov/pubmed/29503930
http://dx.doi.org/10.1016/j.ajoc.2016.09.005

Ejemplares similares